177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours

NCT04375267 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

OTHER_GOV

Sponsor class

Conditions

Clinical Trial, Phase I
Neuroendocrine Tumors
Thymoma
Mesothelioma

Interventions

DRUG: 177Lu-DOTA-TATE + olaparib

Sponsor

Vastra Gotaland Region

Collaborators

[object Object]